Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Opinion & Analysis (NDAQ:PMN)

    Building a Better Covid-19 Antibody Test

    Streetwise Reports May 7, 2020

    Could There Finally Be an Effective Treatment for Alzheimer's Disease?

    Streetwise Reports November 7, 2019

    Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

    Stockhouse Editorial March 28, 2019

    Biotech Releases White Paper on Alzheimer's Disease Candidate

    Streetwise Reports August 2, 2018

    Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

    Streetwise Reports July 11, 2018

    Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

    Streetwise Reports June 28, 2018

    VIDEO: Treating the Root Cause of Alzheimer's

    BTV-Business Television June 21, 2018

    Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

    Streetwise Reports June 13, 2018

    Biotech offers 'best-in-class potential to treat Alzheimer's'

    Streetwise Reports January 11, 2018

    'Hot' Alzheimer's market is promising for biotech with 'novel' drug candidate

    Streetwise Reports November 22, 2017

    Analyst calls biotech with Alzheimer's therapy a 'high risk, high reward opportunity'

    The Life Sciences Report October 26, 2017

    Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

    The Life Sciences Report September 21, 2017

    Biotech with Alzheimer's focus makes progress on several fronts

    The Life Sciences Report July 19, 2017

    The ProMIS of an Alzheimer's cure

    The Life Sciences Report May 4, 2017

    Four biotech mid-caps fund manager Eden Rahim believes have favorable catalysts

    The Life Sciences Report April 6, 2017